The pharmaceutical industry has entered a critical period of transition. With the management of healthcare costs reaching crisis proportions, payers are raising the bar…insisting on hard evidence of clinical and economic value in comparison to therapies that already exist. In this environment, sustainable market leadership requires a radically different development engine.

Managing in a Cost-Constrained Environment, published this month on BIOtechNOW, the blog of BIO, the Biotechnology Industry Organization, NAI Senior Consultant Jill E. Sackman, D.V.M., Ph.D., and Business Analyst Matt Levy, J.D., make the case for a new development process in the pharmaceutical industry, and describe three key steps that companies must take to successfully adopt this process.